WINNIPEG, Canada – Medicure Inc. (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that through its subsidiary, Medicure International Inc., the U.S. Food and Drug Administration (FDA) has granted Fast Track designation...
Latest News
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the Company’s investigational...
SAN FRANCISCO — Medivation, Inc. (Nasdaq: MDVN) today announced the completion of patient enrollment in the CONNECTION study, a six-month, confirmatory, pivotal Phase 3 trial of the investigational drug dimebon in patients with mild-to-moderate Alzheimer’s disease. The international, double-blind, placebo-controlled, pivotal Phase 3 study enrolled 598 patients, exceeding the enrollment...
LOS ANGELES — MEDomics, LLC (www.medomics.com) announces an innovative test for early diagnosis of mitochondrial diseases, a group of disorders that can result in neurological dysfunction, muscle weakness, gastrointestinal symptoms, migraine headaches, blindness, deafness, and diabetes. The MEDomics mitochondrial genome test, MitoDx(TM), uses the revolutionary NextGen sequencing technology to detect...
NEW YORK, Sept. 10, 2021 /PRNewswire/ — Building on a commitment to educate clinicians on rare diseases, Medscape Education, a leading source of accredited medical education for healthcare professionals (HCPs), has launched Pathways In Rare Disease. This dedicated learning center serves as a centralized location for clinicians who are seeking information about how to...
SAN DIEGO – MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, and Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, today announced...
SAN DIEGO & BEDMINSTER, N.J. – MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that utilizes the latest biotechnology to discover and...
WASHINGTON – The Melanoma Research Alliance (MRA) released the following statements from MRA Chief Science Officer Marc Hurlbert, PhD and MRA President & CEO Michael Kaplan on the Food & Drug Administration approval of tebentafusp, the first drug for treating metastatic uveal melanoma: “This approval represents a new day for...
Sixteen-year-old Anthony Melena is an avid history buff. And a sports buff. And he loves to travel. So imagine the thrill he experienced in September when he went to Beijing, China, as part of an American delegation at the 2008 Paralympic Games. “I guess I was speechless (when I heard...
Milwaukee, WI – Kerry Hughes, President and Founder of Harmony 4 Hope (H4H), has been named the Mellowes Center’s Rare Disease Ambassador. Kerry has dedicated her career to elevating the voices of those affected by rare diseases, building impactful partnerships that align with our mission—translating genomic research into real-world advancements...